Symbiotic Health, Inc. – Crohn’s & Colitis Foundation
Symbiotic Health, Inc. develops therapeutics that cure dangerous infections by reversing imbalances in the microbial ecosystem of the gut. Symbiotic Health, Inc. Team: Gerard Honig Bruce Hirsch
Read MoreRadCure
We would like to develop the radiation-enhanced “magic bullet” technology based on targeting viral antigens on cervical and hepatocellular cancers to treat advanced stage patients. RadCure Team: Ekaterina Dadachova Dina…
Read MoreSynthis
Synthis is developing a novel immuno-oncology (IO) therapeutic that reserves immune suppression in metastatic melanoma patients who have failed immune checkpoint blockade. Team: Dori T. Karyat, Ph.D., Founder
Read MoreJibon Health
We provide a low-cost and low-tech emergency obstetrics device for managing PPH in low resource settings. Jibon Health Team: Mikail Kamal Jason Rosenberg
Read MoreNo Brainer
We focus on cryopreservation for primary cell culture commercialization. No Brainer Team: Jason Dictenberg
Read MoreSkinAxis
SkinAxis develops and provides an advanced 3D skin technologies for validation and discovery of drugs and cosmetic active ingredients in physiologically relevant conditions. SkinAxis Team: Arevik Mosoian Luca Gusella Elena…
Read MoreAvalia Immunotherapies
Avalia Immunotherapies – A synthetic immunotherapy platform for self-adjuvanting vaccines, with a unique mode of action, aiming to improve clinical outcomes for cancer, allergy and infectious disease. Avalia Immunotherapies Team:…
Read MorePHD Biosciences
We are developing an enzyme inhibitor with pico-‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-‐negative breast cancer. Nanomedics LLC Team: Michael…
Read MoreSveikatal
Sveikatal, is focused on the management of oral cancer using a novel retinoid therapy, which acts through pathways controlled by Vitamin A and complements current therapies. Sveikatal Team: John Wagner,…
Read MoreNomoCan Pharmaceuticals
Utilizing a novel immunologic approach, NomoCan Pharmaceuticals is developing a targeted therapy for the treatment and prognosis of the most aggressive human cancer, pancreatic cancer. NomoCan Pharmaceuticals Team: Ehsan Sarafraz-Yazdi,…
Read More